María
Chaparro Sánchez
Publicacións nas que colabora con María Chaparro Sánchez (11)
2024
-
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833
-
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758
-
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
2021
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12